Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Off-the-shelf cell therapies for cancer and rare diseases
Empyrean Therapeutics develops off-the-shelf cell therapies intended to make treatments for cancer and rare diseases more accessible. Its approach combines gene editing, stem cell programming and precise genetic control to engineer therapeutic cells. The company is developing cell platforms and manufacturing processes…
Precision oncology biotech targeting novel DNA damage response pathways
Nodus Oncology is a preclinical-stage biotechnology company developing small molecule inhibitors against novel DNA damage response targets for molecularly defined cancer patient populations. The company's pipeline is focused on synthetic lethality and collateral vulnerabilities in tumours with specific DNA repair…
Small molecule drug discovery focused on fibrosis and oncology
Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer. Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule scaffold into two loops, conferring high-affinity target binding with the tissue penetration of small molecules. Its lead programme, a…
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy. The company applies directed evolution and protein engineering to build conditionally activated therapeutics that respond to two simultaneous molecular signals, a design intended to concentrate activity…
DNA nanorobot platform for nucleic acid detection and bioanalysis
Nanovery is a biotechnology company developing a patented Nucleic Acid Nanorobotics (NANs) platform for enzyme-free detection and quantification of nucleic acid targets. Synthetic DNA nanorobots generate fluorescent signals in response to specific sequences, enabling direct quantification of antisense…
3D genomics platform for blood-based clinical diagnostics and precision medicine
Oxford BioDynamics develops blood-based diagnostic tests and precision medicine tools using its proprietary 3D genomics platform. The technology analyses chromosome conformation to identify epigenomic biomarkers linked to disease, prognosis and treatment response. Commercial products include tests for immune…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
Cambridge cancer research institute advancing discovery and clinical translation
Cancer Research UK Cambridge Institute is a cancer research institute within the University of Cambridge, investigating tumour biology, early detection and treatment. Its research groups study cancer evolution, genomics and the tumour microenvironment, using imaging and computational approaches to improve diagnosis…
ML-driven antibody discovery platform for solid tumour therapeutics
LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform. The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability…
Clinical-stage biopharma targeting cancer immunotherapy and obesity
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing small molecule therapies for high unmet medical needs. Its lead programme, POLB 001, is a p38 MAP kinase inhibitor in clinical trials for prevention of cytokine release syndrome associated with CAR-T and bispecific antibody cancer immunotherapies.…
Lentiviral vector platform improving yield for advanced cell therapies
Lentitek is a biotechnology company developing proprietary lentiviral vector manufacturing technology for cell and gene therapy developers. Its platform uses novel promoter engineering to reduce unwanted payload gene expression in manufacturing cell lines, improving vector yield, quality and potency. The technology…
Liquid biopsy platform for isolating circulating tumour cells
Vortex Biosciences develops liquid biopsy technology for isolating circulating tumour cells from whole blood. Its automated, non-contact approach is designed to recover intact, viable cells that can be studied after collection. Preserving cell viability is important for molecular and functional analysis, rather than…
Circulating tumour cell liquid biopsy technology for cancer research and diagnostics
CelLBxHealth is a Guildford-based liquid biopsy company that develops and manufactures microfluidic circulating tumour cell harvesting technology and provides associated laboratory services. Its FDA-cleared instrument captures intact circulating tumour cells from blood samples for downstream genomic, transcriptomic,…
PCR platform enabling precision diagnostics on standard lab instruments
Signatur Biosciences is a biotechnology company developing a molecular diagnostic platform that encodes complex RNA gene expression signatures into single qPCR reactions. The technology enables precision diagnostics to be performed on standard laboratory instruments already present in clinical settings, removing…
Point-of-care diagnostics and AI triage for cancer patients
52North is a medical technology company developing diagnostics and digital tools for urgent cancer care. Its lead programme is a point-of-care blood test designed to help chemotherapy patients assess their risk of neutropenic sepsis outside hospital, alongside an AI-supported app for triaging acute oncology symptoms.…
First-in-class small molecule therapeutics targeting DNA uracilation in cancer
CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule drugs for cancer and inflammatory diseases. Its lead asset CV6-168 is a specific inhibitor of the enzyme dUTPase, inducing uracil misincorporation into cancer cell DNA, triggering DNA damage and immune activation.…
Full-service CRO specialising in oncology and early-phase trials
Pivotal CRO is a full-service contract research organisation providing end-to-end clinical development support across all trial phases, from first-in-human to Phase III. The company offers clinical operations, regulatory affairs, data management, biostatistics, medical monitoring, pharmacovigilance, and patient…
First-in-class small molecule inhibitors of RNA-modifying enzymes
STORM Therapeutics is a clinical-stage biotechnology company pioneering the field of RNA epigenetics, developing small molecule inhibitors of RNA-modifying enzymes as a new class of cancer treatment. Its lead programme STC-15, a METTL3 inhibitor, was the first RNA-modifying enzyme inhibitor to enter human clinical…
Cancer genetics testing and contract research
Oncologica provides molecular cancer diagnostics and contract research services from its laboratory at Chesterford Research Park near Cambridge. Its Oncofocus testing uses tumour DNA profiling to help clinicians identify potentially relevant targeted treatments and immunotherapies. The company also develops…